Effect of Topotecan as Second-Line Chemotherapy for Small Cell Lung Cancer Patients with Interstitial Lung Disease

• DOI: 10.1179/joc.2011.23.6.367
• Publication Date: 2014-01-09T18:06:16Z
• Authors: H.- Suzuki; T.- Hirashima; M.- Kobayashi; S.- Sasada; N. Okamoto; N.- Uehara; Y. Matsuura-; M. Tamiya; N.- Morishita; M.- Higashiguchi; T. Tsumori; I. Kawase
• Keywords: Topotecan

AbstractSmall cell lung cancer with interstitial disease (ILD- SCLC)is difficult to treat because of the risk fatal pneu- monitis. Our study aims evaluate validity topotecan (TOP) as chemotherapy for patients re- lapsed ILD-SCLC. Overall survival was compared between TOP and other drugs second-line treatments ILD- SCLC patients. Forty-seven began treatment administered in 48.5% relapsed cases. The response rate therapy 16.7%. Hematologic toxicities were grade 4 anemia, 3 neutropenia thrombocytope- nia. Mild pulmonary toxicity observed 1 case. Pa- tients receiving showed no significant difference when pa- who underwent regimens (median time 179 vs. 76 days; P =0.76). is a well tolerated drug viable candidate ILD-SCLCpatients.Keywords: LUNG CANCERTOPOTECANPNEUMONIASEC- OND-LINE CHEMOTHERAPYTOXICITY